Ophthalmic Goods · SIC 3851

STAAR SURGICAL CO

STAA

Watch

Latest revenue

$93.5M

as of 2026-04-03

Latest net income

$5.2M

as of 2026-04-03

Net margin

5.6%

as of 2026-04-03

Community sentiment

Where do you think STAA is heading?

1 month
6 months
12 months
5 years
Sign in free to vote and see community sentiment

Keep private notes on STAA — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to add your own notes

STAA vs S&P 500 · rebased to 100

-27.3% / yr 47.0 pts / yr vs S&P 500(S&P 500 +19.7% / yr) 79.6% total
Compare:

Live market

delayed ≤15 min
$29.87
0.30%
Market cap
$1.48B
Enterprise value
$1.35B
P/E (trailing)
Forward P/E
P/B
4.20×
Dividend yield
0.0%
52-wk high
$35.87
52-wk low
$15.59
Beta
Shares out
49.5M

What this company does

AI

ITEM 1. Business STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. Unless the context indicates otherwise, “we,” “us,” the “Company,” and…

AI summary unavailable — showing raw filing excerpt

Generated from STAA's filing dated 2026-03-03

Key risks

AI

ITEM 1A. Risk Factors Investment in our securities involves a high degree of risk. Investors should carefully consider the following risk factors, in addition to other information contained in this Annual Report and other filings that we make from time to time with the SEC, before making a decision to invest in our common stock. Any of the following risks, as well as other risks that we cannot foresee at this time or that we currently view to be immaterial, could materially and adversely affect our business, financial condition, results of operations or cash flows. The trading price of our common stock could decline due to any of these risks, and investors may lose all or part of their…

AI summary unavailable — showing raw filing excerpt

Generated from STAA's filing dated 2026-03-03

4.2
of 10

ActaClear Score

Neutral
#6 of 7 in Ophthalmic Goods
+0.0 · 5d
Profitability·25%
3.9
Growth·15%
1.7
Value·20%
0.8
Quality·20%
Momentum·20%
10.0

Computed from 5 years of SEC fundamentals + latest market data, ranked within Ophthalmic Goods (7 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.